Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Deals M & A Cancer

Pfizer-gen? Pfizer Is The Latest Rumored Suitor For Seagen

  • Analysis

Executive Summary

Pfizer and Seagen reportedly are in merger discussions, signaling Pfizer’s willingness to invest significantly in antibody-drug conjugates (ADCs) for cancer.

You may also be interested in...



Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs

Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.

Seagen To Surge Ahead As ADCs Become Frontline Cancer Therapies

Putting its CEO crisis and takeover rumors behind it, Seagen has big plans to expand its leading position in antibody-drug conjugates in 2023.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Deals M & A Cancer
Latest Headlines

Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value

AbbVie Spends $10bn On ImmunoGen To Improve Chances In ADC Space

Galderma Highlights Fast Onset, Durability Data For Potential Botox Rival

Olema Boosts Its Partnering Position With SERD Combo Data

See All
UsernamePublicRestriction

Register

SC147971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By